PHARMA
CadilaHealthCareCadila is Good to Go Long at 440 for Investment Purpose.
Only for Educational Purpose.
Astrazeneca - Looks good aheadThe stock has given a breakout with good volumes on the daily time frame. Also, MACD is showing reversal signs. If sustained above the support channel may go to the levels of 4000+.
Only for learning and sharing purposes, not a bit of trading advice.
Please comment with your views.
All the best.
Range BreakoutThe stock has been in Consolidation for more than 7 Months and tried to break out several times.
Volume has increased significantly in the last trading session.
200 EMA acting as a strong support.
Looks good above 992 for swing trading with STPL below 865.
With the new COVID Variant, Pharma stocks are on the rise, so by the looks of it, this is a high probable Trade set up.
Swing Trading Opportunities for the week beginning 29-11-21SWING TRADING WATCHLIST FOR THE WEEK BEGINNING 29-11-21
INTENT
I will only be sharing the time frame and the scrip name. I will leave the trade basis aside as the intent is to engage the reader in learning the basics of finding good scrips. You can have a look at the charts and place your favorite indicators and check out if any of these fit your trade plan.
Some readers feel that I am simply listing down several scrips so that if they go up I can claim so. This is not the case - I am not here to score any points. I am sharing my weekly analysis and if you like it, read it and if you do not agree, I am fine with that.
ON MY WATCHLIST FOR THE COMING WEEK
For you to get a better perspective of the reasons behind this week’s post, I recommend that you read/watch the video on the Weekly Analysis of Indices posted by me separately. This week is different than usual as we had only a 4 day week trading week whereas the world was open on Friday as well and a lot has happened on that day in the global markets due to reimposed lockdown in Austria and likely actions by other European countries.
CAUTION - Please read this week’s post bearing in mind the fact the market situation has already changed in a day and it may further change by the time you have read and watched the video. So please take due care and apply due diligence before making any buy decision in any of the scrips listed here.
This is a weekly review of the available opportunities so my time frame for analysis moves from Daily to Weekly and from Hourly to Daily. Here are the likely candidates for the week -
SECTORS LOOKING GOOD FOR LONG POSITIONS-
Auto
Commodities
IT
Media
Pharma
If the Covid related negative sentiment persits during the week, IT, Media and Pharma are likely to do better than the other sectors.
There are many sectors such as Private Banks and PSU Banks that have closed around their 50 Weekly MA, however, I have not included them as these would be most sensitive to any negativity that may set in the sentiments.
WEEKLY TIME FRAME- FOR LONG POSITIONS - Nifty Spot at 17006
Federal Bank
HDFC
HUL
Infosys
Reliance
Tata Consumer
Tata Steel
UPL
Ajanta Pharma
Emami Ltd
NCC
Laurus Labs
Lupin
Tata Communications
ZEEL
Alembic Pharma
The market is at an uncertain level and as I write this, Maharashtra has kicked in RT-PCR tests or full vaccination as the barriers to entry into the state. This clearly shows that this time around, no one wants to be taken off guard and the market may react suitably as Mumbai is the Commercial capital of the country.
I may / may not take these trades as not every opportunity should / can be traded.
I believe that it is better to help someone learn the technique of selecting good scrips than giving tips - in any case, I am not SEBI regd so I do not have the authority as well to do so.
In case you are able to spot the setup and the trade basis, please do share so that together we can learn.
Here is the Video Link:
Thank you for your time and Happy Learning,
27-11--21
Disclaimer -- This post is shared for learning and educational purposes only and in no way acts as a recommendation. I am not a SEBI regd trader so please either decide your trades/investments on your own or consult your financial advisor before making any trades.
Aurobindo Pharma Technical and Fundamental AnalysisTechnical Analysis
Aurobindo Pharma has taken support at upper range of support box(630). It can move upwards after taking support at 630 price level. It is good time to accumulate share at current levels for long term.
Fundamental Analysis
Current PE : 7.45 (Undervalued in comparison to peer Pharma stocks)
Sector PE : 38.7
Below data for previous 5 years.
Revenue Growth : 15.2%
Sector Revenue Growth : 6.96%
Market share increased from 7.65% to 11%
Net income growth : 21.4%
Sector Net income growth : 8%
AUROPHARMA: Fundamentally cheap and expected reversalTarget of at least 900. Probable formation of a W pattern. If it breaks 750 levels it will hit 900. The stock has previously taken support in the current levels. Good opportunity to buy this dip. And above all of this, this stock is fundamentally undervalued. The most and probably only undervalued stock in Indian Pharma.
Laurus Labs: Is it making a comeback...Simple price analysis of Laurus Labs.
Laurus Labs, currently has found a support at around 450 and has made reversal.
Critical thing to note would be when Laurus Labs crosses the 200 day EMA, at around 529. Need to check other supporting parameters to see if the turnaround is in the corner.
The RSI has reversed from 40 and is currently at 46. Positive trigger would be if it breaches 60 and moves up towards 70
Observe the volume bars. Dried up volume would set the stage for revival. Should wait and watch.
In the long term I am bullish, though I have exited the stock at 600. Will enter if technical parameters are favourable.
Biocon For Long ?1.Falling Wedge forming in weekly chart
2.Nifty Pharma Index is also bounce from support area
3.Stock is also bounce from demand area
4.RSI Divergence In Daily Chart
5.Stock is near 0.618
THIS ANALYSIS FOR ONLY EDUCATIONAL PURPOSE
-THANK YOU FOR YOUR TIME
ALWAYS PUT YOUR STOPLOSS 1ST
VIMTA Labs LONG after multiyear breakoutVimta Labs is engaged in the business of testing food and drugs. It also does contract research for clinical research and pre-clinical studies.
Company was expected to give good quarter and has delivered.
VIMTA LABS: Q2 CONS NET PROFIT 97M RUPEES VS 75M (YOY); 81M (QOQ) || Q2 REVENUE 754M RUPEES VS 593M (YOY); 613M (QOQ)
DII have bought significantly in the last quarter, Some news is coming up
TARGET : See CHART
Aarti Drugs Analysis for Short termAarti Drugs is moving in a Descending triangle pattern from Aug 2020 and may give a break out shortly. Even though the pattern is bearish, I'm quite bullish about this stock bcz it's a market leader in API supply with a market share of 79% and API market will only grow with time to reduce dependence on China. So Buying it now with a SL at 575 can prove to be a Jackpot in Short tern] and long term.